Clovis Oncology’s Rubraca (rucaparib) has been designated as a Breakthrough Therapy by the FDA in prostate cancer, paving the way for a faster review if clinical trials work out. The FDA has ...

Recent FDA approvals have included Rubraca (rucaparib), which was approved in 2020 for patients with metastatic castration-resistant prostate cancer that expresses a BRCA mutation, and Lynparza ...

Scientists that discovered a life-saving drug to treat cancer patients with a faulty gene are marking a special anniversary, and looking back at the impact their work has had around the world.

A drug used against cancer could also be effective against severe coronavirus infection.

Professor Ruth Plummer, Director of the Cancer Research UK Newcastle Centre, and Professor Herbie Newell, Emeritus Professor of Cancer Therapeutics at Newcastle University, were among the team, funded ...

However, the approaches within these trials resemble the Olaparib trials. Rucaparib and Niraparib are being investigated in platinum sensitive ovarian cancers as a maintenance therapy (NCT01968213 ...

Nov. 6, 2024 — Sewage surveillance is emerging as a powerful tool in the fight against antimicrobial resistance with the potential to protect vulnerable communities more ... Nov. 6, 2024 ...

can make Bendeka less effective rucaparib (Rubraca) — can increase the risk of side effects of Bendeka zafirlukast (Accolate) — can increase the risk of side effects of Bendeka In some cases ...

Japanese gynecological benign tumor market is thriving with cutting-edge diagnostic technologies and minimally invasive ...

Nov. 1, 2024 — Microplastics have been steadily increasing in freshwater environments for decades and are directly tied to rising global plastic production since the 1950s, according to a new ...

November 4, 2024 • How did life start on Earth? The answer is a big scientific mystery scientists are actively investigating. After talking with many scientists, host Regina G. Barber found that ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...